A cytokine-based neuroimmunologic mechanism of cancer-related symptoms Journal Article


Authors: Lee, B. N.; Dantzer, R.; Langley, K. E.; Bennett, G. J.; Dougherty, P. M.; Dunn, A. J.; Meyers, C. A.; Miller, A. H.; Payne, R.; Reuben, J.; Wang, X. S.; Cleeland, C. S.
Article Title: A cytokine-based neuroimmunologic mechanism of cancer-related symptoms
Abstract: While many of the multiple symptoms that cancer patients have are due to the disease, it is increasingly recognized that pain, fatigue, sleep disturbance, cognitive dysfunction and affective symptoms are treatment related, and may lead to treatment delays or premature treatment termination. This symptom burden, a subjective counterpart of tumor burden, causes significant distress. Progress in understanding the mechanisms that underlie these symptoms may lead to new therapies for symptom control. Recently, some of these symptoms have been related to the actions of certain cytokines that produce a constellation of symptoms and behavioral signs when given exogenously to both humans and animals. The cytokine-induced sickness behavior that occurs in animals after the administration of infectious or inflammatory agents or certain proinflammatory cytokines has much in common with the symptoms experienced by cancer patients. Accordingly, we propose that cancer-related symptom clusters share common cytokine-based neuroimmunologic mechanisms. In this review, we provide evidence from clinical and animal studies that correlate the altered cytokine profile with cancer-related symptoms. We also propose that the expression of coexisting symptoms is linked to the deregulated activity of nuclear factor-kappa B, the transcription factor responsible for the production of cytokines and mediators of the inflammatory responses due to cancer and/or cancer treatment. These concepts open exciting new avenues for translational research in the pathophysiology and treatment of cancer-related symptoms. Copyright © 2004 S. Karger AG, Basel.
Keywords: cancer chemotherapy; cancer survival; clinical trial; fatigue; review; cisplatin; dose response; drug efficacy; nonhuman; side effect; alpha interferon; paclitaxel; cancer radiotherapy; cancer staging; anorexia; neoplasms; interleukin 2; unindexed drug; melanoma; quality of life; bortezomib; pain; breast cancer; cluster analysis; nausea; neuropathy; interleukin 1 receptor blocking agent; vincristine; cancer pain; drug potency; food intake; kidney carcinoma; depression; cytokine; cytokines; statistical significance; tumor necrosis factor alpha; immunotherapy; gamma interferon; acetylsalicylic acid; paracetamol; cyclooxygenase 2 inhibitor; stroke; ibuprofen; nonsteroid antiinflammatory agent; interleukin 6; glucocorticoid; tamoxifen; lipopolysaccharide; cognitive defect; flavonoid; virus infection; headache; immunomodulating agent; vinca alkaloid; cachexia; taxane derivative; sensory dysfunction; motor dysfunction; verbal memory; tacrolimus; bacterial infection; granulocyte colony stimulating factor; neuropathic pain; amnesia; brain function; interleukin 1; ear reconstruction; hippocampus; salicylic acid; chronic leukemia; language disability; animal behavior; cognitive impairment; prostaglandin synthase inhibitor; nuclear factor-kappa b; cyclopentenone derivative; cancer; humans; human; priority journal; cancer-related symptoms; sickness behavior; neuroimmunology; neuroimmunomodulation
Journal Title: Neuroimmunomodulation
Volume: 11
Issue: 5
ISSN: 1021-7401
Publisher: Karger  
Date Published: 2004-01-01
Start Page: 279
End Page: 292
Language: English
DOI: 10.1159/000079408
PROVIDER: scopus
PUBMED: 15316238
DOI/URL:
Notes: NeuroImmunomodulation -- Cited By (since 1996):135 -- Export Date: 16 June 2014 -- CODEN: NROIE -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard Payne
    68 Payne